These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16419262)

  • 1. Introduction: background, issues, and recommendations from the conference.
    Mauck C
    J Acquir Immune Defic Syndr; 2004 Oct; 37 Suppl 3():S143-9. PubMed ID: 16419262
    [No Abstract]   [Full Text] [Related]  

  • 2. The CONRAD/WHO Update 2000 colposcopy manual: how well is it working?
    Njoroge B; Chirenje ZM; Pandey B; Mirembe F; Joshi S; Low-Beer N; Maslankowski LA
    J Acquir Immune Defic Syndr; 2004 Oct; 37 Suppl 3():S150-1. PubMed ID: 16419263
    [No Abstract]   [Full Text] [Related]  

  • 3. Vaginal microbicides: moving ahead after an unexpected setback.
    van de Wijgert JH; Shattock RJ
    AIDS; 2007 Nov; 21(18):2369-76. PubMed ID: 18025873
    [No Abstract]   [Full Text] [Related]  

  • 4. Current and future microbicide approaches aimed at preventing HIV infection in women.
    Pozzetto B; Delézay O; Brunon-Gagneux A; Hamzeh-Cognasse H; Lucht F; Bourlet T
    Expert Rev Anti Infect Ther; 2012 Feb; 10(2):167-83. PubMed ID: 22339191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing inflammation and epithelial integrity in vaginal product research. Proceedings of a workshop. November 19-21, 2003. Dominican Republic.
    J Acquir Immune Defic Syndr; 2004 Oct; 37 Suppl 3():S143-200. PubMed ID: 16479634
    [No Abstract]   [Full Text] [Related]  

  • 6. Microbicides may be ready.
    AIDS Patient Care STDS; 2002 May; 16(5):243. PubMed ID: 12055033
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of biopsy in vaginal microbicide development.
    Low-Beer N
    J Acquir Immune Defic Syndr; 2004 Oct; 37 Suppl 3():S181-3. PubMed ID: 16419270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances on anti-HIV vaginal delivery systems development.
    Antimisiaris SG; Mourtas S
    Adv Drug Deliv Rev; 2015 Sep; 92():123-45. PubMed ID: 25858666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaginal microbicides and the prevention of HIV transmission.
    Cutler B; Justman J
    Lancet Infect Dis; 2008 Nov; 8(11):685-97. PubMed ID: 18992405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting the reproducibility and validity of colposcopy for product development: review of current literature.
    Ballagh S
    J Acquir Immune Defic Syndr; 2004 Oct; 37 Suppl 3():S152-5. PubMed ID: 16419264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guiding the vaginal microbicide trials with biomarkers of inflammation.
    Fichorova RN
    J Acquir Immune Defic Syndr; 2004 Oct; 37 Suppl 3(Suppl 3):S184-93. PubMed ID: 16419271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model.
    Destache CJ; Mandal S; Yuan Z; Kang G; Date AA; Lu W; Shibata A; Pham R; Bruck P; Rezich M; Zhou Y; Vivekanandan R; Fletcher CV; Li Q
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3633-9. PubMed ID: 27044548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV/AIDS. At last, vaginal gel scores victory against HIV.
    Cohen J
    Science; 2010 Jul; 329(5990):374-5. PubMed ID: 20643914
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits.
    Clark MR; Friend DR
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1458-66. PubMed ID: 22394281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV topical microbicides: the current development strategy is fully justified.
    Stone AB
    Am J Public Health; 2004 Nov; 94(11):1845-6; author reply 1846-7. PubMed ID: 15514217
    [No Abstract]   [Full Text] [Related]  

  • 16. Digital assessment of the reproductive tract (DART).
    Jamshidi R; Blumenthal P
    J Acquir Immune Defic Syndr; 2004 Oct; 37 Suppl 3():S171-3. PubMed ID: 16419268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microbicides and other topical strategies to prevent vaginal transmission of HIV.
    Lederman MM; Offord RE; Hartley O
    Nat Rev Immunol; 2006 May; 6(5):371-82. PubMed ID: 16639430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical assessment of the proinflammatory potential of microbicide candidates.
    Doncel GF; Chandra N; Fichorova RN
    J Acquir Immune Defic Syndr; 2004 Oct; 37 Suppl 3():S174-80. PubMed ID: 16419269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
    Nel AM; Coplan P; van de Wijgert JH; Kapiga SH; von Mollendorf C; Geubbels E; Vyankandondera J; Rees HV; Masenga G; Kiwelu I; Moyes J; Smythe SC
    AIDS; 2009 Jul; 23(12):1531-8. PubMed ID: 19550287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The design of prophylactic trials for HIV: the case of microbicides.
    Stein ZA; Myer L; Susser M
    Epidemiology; 2003 Jan; 14(1):80-3; discussion 83-4. PubMed ID: 12500050
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.